Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6362031 | 0.94 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL6353569 | 0.88 | MAPT (0.40) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL6358103 | 0.88 | ALDH1A1 (0.45) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL8412728 | 0.87 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL6357186 | 0.83 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL6358100 | 0.83 | ALDH1A1 (0.40) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL6357895 | 0.81 | RORC (0.49) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL6358821 | 0.79 | CTSK (0.44) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL6362032 | 0.78 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL6362871 | 0.77 | ALDH1A1 (0.39) | ALDH1A1KDM4EHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154062-A1 | Substituted chiral allosteric hemoglobin modifiers | ALLOS THERAPEUTICS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-6894185-B2 | Substituted chiral allosteric hemoglobin modifiers | Allós Therapeutics, Inc. (US) | 2005-05-17 | — | — | US | disclosed |
| EP-1206442-A4 | SUBSTITUTED CHIRAL ALLOSTERIC HEMOGLOBIN MODIFIERS | UNIV VIRGINIA COMMONWEALTH (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20030130523-A1 | Substituted chiral allosteric hemoglobin modifiers | ABRAHAM DONALD J (US) | 2003-07-10 | — | — | US | disclosed |
| US-6486342-B1 | Substituted chiral allosteric hemoglobin modifiers | VIRGINIA COMMONWEALTH UNIVERSITY | 2002-11-26 | — | — | US | disclosed |
| EP-1206442-A1 | SUBSTITUTED CHIRAL ALLOSTERIC HEMOGLOBIN MODIFIERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001014316-A1 | SUBSTITUTED CHIRAL ALLOSTERIC HEMOGLOBIN MODIFIERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130523-A1 | Substituted chiral allosteric hemoglobin modifiers | HBZ, HBB, HBG2 | ALDH1A1 4454/4885KDM4E 809/4885HPGD 1583/4885 |
| US-20050154062-A1 | Substituted chiral allosteric hemoglobin modifiers | HBZ, HBB, HBG2 | ALDH1A1 4454/4885KDM4E 809/4885HPGD 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.